Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800444366> ?p ?o ?g. }
- W2800444366 endingPage "22497" @default.
- W2800444366 startingPage "22480" @default.
- W2800444366 abstract "// Shunsuke Itai 1, 2 , Tomokazu Ohishi 3 , Mika K. Kaneko 1 , Shinji Yamada 1 , Shinji Abe 4, 5 , Takuro Nakamura 1 , Miyuki Yanaka 1 , Yao-Wen Chang 1 , Shun-Ichi Ohba 3 , Yasuhiko Nishioka 5 , Manabu Kawada 3 , Hiroyuki Harada 2 and Yukinari Kato 1, 6 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi 980-8575, Japan 2 Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan 3 Institute of Microbial Chemistry, BIKAKEN, Numazu, Microbial Chemistry Research Foundation, Numazu-shi, Shizuoka 410-0301, Japan 4 Department of Clinical Pharmacy Practice Pedagogy, Graduate School of Biomedical Sciences, Tokushima University, Tokushima 770-8505, Japan 5 Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima 770-8503, Japan 6 New Industry Creation Hatchery Center, Tohoku University, Aoba-ku, Sendai, Miyagi 980-8575, Japan Correspondence to: Yukinari Kato, email: yukinarikato@med.tohoku.ac.jp , yukinari-k@bea.hi-ho.ne.jp Keywords: podocalyxin; PODXL; monoclonal antibody; antibody-dependent cellular cytotoxicity; oral squamous cell carcinoma Received: October 26, 2017 Accepted: March 24, 2018 Published: April 27, 2018 ABSTRACT Podocalyxin (PODXL) overexpression is associated with progression, metastasis, and poor outcomes in cancers. We recently produced the novel anti-PODXL monoclonal antibody (mAb) PcMab-47 (IgG 1 , kappa). Herein, we engineered PcMab-47 into 47-mG 2a , a mouse IgG 2a -type mAb, to add antibody-dependent cellular cytotoxicity (ADCC). We further developed 47-mG 2a -f, a core fucose-deficient type of 47-mG 2a to augment its ADCC. Immunohistochemical analysis of oral cancer tissues using PcMab-47 and 47-mG 2a revealed that the latter stained oral squamous cell carcinoma (OSCC) cells in a cytoplasmic pattern at a much lower concentration. PcMab-47 and 47-mG 2a detected PODXL in 163/201 (81.1%) and in 197/201 (98.0%) OSCC samples, respectively. 47-mG 2a -f also detected PODXL in OSCCs at a similar frequency as 47-mG 2a . In vitro analysis revealed that both 47-mG 2a and 47-mG 2a -f exhibited strong complement-dependent cytotoxicity (CDC) against CHO/hPODXL cells. In contrast, 47-mG 2a -f exhibited much stronger ADCC than 47-mG 2a against OSCC cells, indicating that ADCC and CDC of those anti-PODXL mAbs depend on target cells. In vivo analysis revealed that both 47-mG 2a and 47-mG 2a -f exerted antitumor activity in CHO/hPODXL xenograft models at a dose of 100 μg or 500 μg/mouse/week administered twice. 47-mG 2a -f, but not 47-mG 2a , exerted antitumor activity in SAS and HSC-2 xenograft models at a dose of 100 μg/mouse/week administered three times. Although both 47-mG 2a and 47-mG 2a -f exerted antitumor activity in HSC-2 xenograft models at a dose of 500 μg/mouse/week administered twice, 47-mG 2a -f also showed higher antitumor activity than 47-mG 2a . These results suggested that a core fucose-deficient anti-PODXL mAb could be useful for antibody-based therapy against PODXL-expressing OSCCs." @default.
- W2800444366 created "2018-05-17" @default.
- W2800444366 creator A5000775867 @default.
- W2800444366 creator A5016361449 @default.
- W2800444366 creator A5016375050 @default.
- W2800444366 creator A5018371636 @default.
- W2800444366 creator A5025137523 @default.
- W2800444366 creator A5026376260 @default.
- W2800444366 creator A5032655219 @default.
- W2800444366 creator A5034011259 @default.
- W2800444366 creator A5060363731 @default.
- W2800444366 creator A5064054143 @default.
- W2800444366 creator A5067408189 @default.
- W2800444366 creator A5072443693 @default.
- W2800444366 creator A5077624041 @default.
- W2800444366 date "2018-04-27" @default.
- W2800444366 modified "2023-09-24" @default.
- W2800444366 title "Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma" @default.
- W2800444366 cites W1477783513 @default.
- W2800444366 cites W1836239578 @default.
- W2800444366 cites W1972042205 @default.
- W2800444366 cites W1998297552 @default.
- W2800444366 cites W2005453542 @default.
- W2800444366 cites W2006796442 @default.
- W2800444366 cites W2024752922 @default.
- W2800444366 cites W2025915231 @default.
- W2800444366 cites W2030120255 @default.
- W2800444366 cites W2057320149 @default.
- W2800444366 cites W2059799534 @default.
- W2800444366 cites W2066692548 @default.
- W2800444366 cites W2076247294 @default.
- W2800444366 cites W2076833801 @default.
- W2800444366 cites W2081867678 @default.
- W2800444366 cites W2084136419 @default.
- W2800444366 cites W2091996572 @default.
- W2800444366 cites W2098567941 @default.
- W2800444366 cites W2101120866 @default.
- W2800444366 cites W2102786252 @default.
- W2800444366 cites W2104810134 @default.
- W2800444366 cites W2112845420 @default.
- W2800444366 cites W2112965812 @default.
- W2800444366 cites W2117955175 @default.
- W2800444366 cites W2121197576 @default.
- W2800444366 cites W2122935174 @default.
- W2800444366 cites W2132002425 @default.
- W2800444366 cites W2138367897 @default.
- W2800444366 cites W2144746279 @default.
- W2800444366 cites W2149523673 @default.
- W2800444366 cites W2154305402 @default.
- W2800444366 cites W2155062057 @default.
- W2800444366 cites W2155384808 @default.
- W2800444366 cites W2160936126 @default.
- W2800444366 cites W2163833204 @default.
- W2800444366 cites W2167889022 @default.
- W2800444366 cites W2171390158 @default.
- W2800444366 cites W2235523093 @default.
- W2800444366 cites W2329824702 @default.
- W2800444366 cites W2401857520 @default.
- W2800444366 cites W2430814939 @default.
- W2800444366 cites W2511684249 @default.
- W2800444366 cites W2529484692 @default.
- W2800444366 cites W2566927463 @default.
- W2800444366 cites W2571830238 @default.
- W2800444366 cites W2591836828 @default.
- W2800444366 cites W2597739773 @default.
- W2800444366 cites W2607011855 @default.
- W2800444366 cites W2613226078 @default.
- W2800444366 cites W2613816154 @default.
- W2800444366 cites W2616025468 @default.
- W2800444366 cites W2639623121 @default.
- W2800444366 cites W2728262959 @default.
- W2800444366 cites W2736282016 @default.
- W2800444366 cites W2755413521 @default.
- W2800444366 doi "https://doi.org/10.18632/oncotarget.25132" @default.
- W2800444366 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5976479" @default.
- W2800444366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29854293" @default.
- W2800444366 hasPublicationYear "2018" @default.
- W2800444366 type Work @default.
- W2800444366 sameAs 2800444366 @default.
- W2800444366 citedByCount "28" @default.
- W2800444366 countsByYear W28004443662018 @default.
- W2800444366 countsByYear W28004443662020 @default.
- W2800444366 countsByYear W28004443662021 @default.
- W2800444366 countsByYear W28004443662022 @default.
- W2800444366 countsByYear W28004443662023 @default.
- W2800444366 crossrefType "journal-article" @default.
- W2800444366 hasAuthorship W2800444366A5000775867 @default.
- W2800444366 hasAuthorship W2800444366A5016361449 @default.
- W2800444366 hasAuthorship W2800444366A5016375050 @default.
- W2800444366 hasAuthorship W2800444366A5018371636 @default.
- W2800444366 hasAuthorship W2800444366A5025137523 @default.
- W2800444366 hasAuthorship W2800444366A5026376260 @default.
- W2800444366 hasAuthorship W2800444366A5032655219 @default.
- W2800444366 hasAuthorship W2800444366A5034011259 @default.
- W2800444366 hasAuthorship W2800444366A5060363731 @default.
- W2800444366 hasAuthorship W2800444366A5064054143 @default.
- W2800444366 hasAuthorship W2800444366A5067408189 @default.
- W2800444366 hasAuthorship W2800444366A5072443693 @default.